Short answer
Personalis, Inc. (PSNL) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $26M (up 76.6% year over year) with net income of −$34M.
Q3 2026 key financials · XBRL
- Revenue
- $26M
- +76.6% YoY · +14.5% QoQ
- Net income
- −$34M
- −56.1% YoY · −6.7% QoQ
- Operating margin
- -138.8%
- EPS (diluted)
- −$0.31
- −29.2% YoY · −3.3% QoQ
Source: XBRL data from the Personalis, Inc. (PSNL) Q3 2026 10-Q on SEC EDGAR. USD.
Personalis, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $25.6M, up 77% YoY from $14.5M, driven by pharma, clinical diagnostics and population sequencing
- Operating margin -138.8% vs -160.7% YoY, calculated from operating losses of $35.5M and $23.3M
- Best segment: clinical diagnostics $4.4M, up 1,039% YoY; worst: enterprise sales, down 99%
- Cash and investments $190.6M vs $240.0M at year-end; nine-month operating cash use $75.3M
- 2026 capital expenditures expected at $10.0M-$12.0M; headwinds include reimbursement-related testing costs and Merger uncertainty
Risk Factors
- Pending Tempus merger, stockholder vote scheduled November 30, 2026, creates new completion and timing risk
- Merger consideration, fixed exchange ratio 0.3356 below Tempus Floor Price $48.42, could value shares below $16.25
- New tariff exposure, announced U.S. tariffs may raise laboratory costs that fixed-price contracts cannot immediately recover
- Regulatory compliance, FDA could require medical-device authorization for LDTs, adding premarket review and ongoing obligations
- Customer concentration, Moderna 13%, VA MVP 15%, and Merck 27% of nine-month 2026 revenue intensify renewal risk
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Personalis, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.